Arnold & Porter: DOJ Announces Controlled Substances Act Scheduling Changes for FDA-Approved Marijuana and State-Licensed Medical Marijuana Products
April 27, 2026 Advisory By Howard Sklamberg Michelle F. Gillice Burden H. Walker Elizabeth Trentacost Nataniel Tsai On April 23, 2026, the U.S. Department of Justice (DOJ), in conjunction with the Drug Enforcement Administration (DEA), announced that pursuant to...
Bradley: Is the Most Impactful Part of Marijuana Rescheduling an Obscure Sentence in the Tax Code?
This is the second of 13 posts describing the impacts of marijuana’s rescheduling. An homage to Phish’s historic run at Madison Square Garden in the Summer of 2017, Budding Trends Baker’s Dozen will address how rescheduling affects various areas of the law and our...
Akerman: DOJ Reclassifies Medical Marijuana to Schedule III: Key Implications for Florida and National Cannabis Operators
April 28, 2026 By Austin A.B. Ownbey The U.S. Department of Justice (DOJ) has announced a landmark shift in federal cannabis policy, reclassifying certain cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). As reported by the Associated...
Holon Law Partners’ Statement on Medical Marijuana Rescheduling Announcement
April 28, 2026 Marking a significant moment in the path to end federal cannabis prohibition, the U.S. Department of Justice (“DOJ”) and the Drug Enforcement Administration (“DEA”) issued an April 23, 2026 Final Order (the “Order”) proposing to immediately reclassify...
Dentons: Breaking: DOJ Reschedules and Provides a Pathway for Full Legalization of Medical Cannabis
Medical cannabis products moved to Schedule III and to become fully legal with DEA Registration; Possibility for Adult-Use Rescheduling in Upcoming Hearing April 23, 2026 Today’s development – April 23, 2026 Medical Cannabis Rescheduled with Legalization Pathway: DOJ...Top 200 Cannabis Lawyers
We Support